Empirical Financial Services LLC d.b.a. Empirical Wealth Management Boosts Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 4.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 45,223 shares of the medical equipment provider’s stock after acquiring an additional 2,064 shares during the quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Hologic were worth $3,231,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Commonwealth Equity Services LLC grew its position in shares of Hologic by 27.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 74,949 shares of the medical equipment provider’s stock worth $5,201,000 after buying an additional 16,319 shares during the last quarter. Raymond James & Associates lifted its holdings in shares of Hologic by 3.0% during the 3rd quarter. Raymond James & Associates now owns 252,013 shares of the medical equipment provider’s stock valued at $17,490,000 after purchasing an additional 7,407 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Hologic by 10.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 282,113 shares of the medical equipment provider’s stock worth $19,579,000 after purchasing an additional 25,614 shares in the last quarter. Mackenzie Financial Corp grew its stake in Hologic by 11.4% during the 3rd quarter. Mackenzie Financial Corp now owns 65,414 shares of the medical equipment provider’s stock worth $4,533,000 after buying an additional 6,671 shares during the last quarter. Finally, IFM Investors Pty Ltd increased its position in Hologic by 1.6% during the 3rd quarter. IFM Investors Pty Ltd now owns 53,746 shares of the medical equipment provider’s stock valued at $3,730,000 after buying an additional 863 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Up 0.2 %

NASDAQ:HOLX traded up $0.17 during trading hours on Tuesday, hitting $76.10. The company had a trading volume of 984,581 shares, compared to its average volume of 1,743,900. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $86.74. The company has a market cap of $17.86 billion, a P/E ratio of 38.74, a P/E/G ratio of 2.55 and a beta of 1.01. The company has a 50-day moving average of $76.15 and a 200 day moving average of $73.14. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the prior year, the firm posted $1.06 earnings per share. Hologic’s quarterly revenue was down .8% on a year-over-year basis. Sell-side analysts expect that Hologic, Inc. will post 4.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on HOLX shares. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. UBS Group upped their target price on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. JPMorgan Chase & Co. lifted their price target on Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research report on Friday. Raymond James increased their price objective on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Finally, Citigroup raised Hologic from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.56.

Insider Transactions at Hologic

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The disclosure for this sale can be found here. Insiders own 1.75% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.